Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracers could illuminate immune battle inside lung tumors

NCT ID NCT06457789

Diagnosis Sponsor: Amsterdam UMC, location VUmc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial is testing two experimental PET imaging tracers to see if they can show T cell activity in lung cancer tumors. People with non-small cell lung cancer who are about to have surgery after standard chemo-immunotherapy will receive two PET scans. The scans will be compared to each other and to the removed tumor tissue to see if the tracers accurately reflect immune cell presence and activation. The goal is to find better ways to predict how well immunotherapy works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two experimental PET imaging tracers, [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab, are injected to visualize T cells in tumors.
What this could lead to
If successful, this could lead to better imaging methods to predict which lung cancer patients will respond to immunotherapy, enabling more personalized treatment.
What could go wrong
This is an early-stage imaging study with a small number of patients. The tracers may not accurately reflect immune activity, and results may not translate to broader clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed NSCLC * T1-4N0-2, lesion size of ≥2cm, at time of the restaging FDG PET/CT * Planned to undergo resection after chemo-IO according to routine treatment guidelines * Willing and able to provide written informed consent for the trial * Above 18 years of age on day of signing informed consent * Have measurable disease based on RECIST 1.1 * Have a ECOG performance status of 0-1, and are considered operable based on pulmonary function test and/or exercise testing Exclusion Criteria: * Patients deemed inoperable * Patients who have received a splenectomy * Patients who have received any vaccination within 14 days of enrollment * Patients with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid \>10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. * Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC, location VUmc

    RECRUITING

    Amsterdam, North Holland, 1081 HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.